Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned.
about
Pulmonary perfusion and xenon gas exchange in rats: MR imaging with intravenous injection of hyperpolarized 129XeRisk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysisA window on disease pathogenesis and potential therapeutic strategies: molecular imaging for arthritis.Is macrocycle a synonym for kinetic inertness in Gd(III) Complexes? Effect of coordinating and noncoordinating substituents on inertness and relaxivity of Gd(III) chelates with DO3A-like ligands.Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.Non-gadolinium-enhanced 3-dimensional magnetic resonance angiography for the evaluation of thoracic aortic disease: a preliminary experience.Nephrogenic systemic fibrosis in liver disease: a systematic review.The fate of Gd and chelate following intravenous injection of gadodiamide in rats.Contrast-enhanced whole-heart coronary magnetic resonance angiography at 3 T using interleaved echo planar imaging.Integrating carthage-specific T1rho MRI into knee clinic diagnostic imaging.Gadolinium Enhanced MR-angiography Results in Patients With Peripheral Arterial Disease: Positive Predictive Value Compared to Surgery.Repeatability of a dual gradient-recalled echo MRI method for monitoring post-isometric contraction blood volume and oxygenation changes.An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis.Is Non-Contrast CT Adequate for the Evaluation of Hepatic Metastasis in Patients Who Cannot Receive Iodinated Contrast Media?Single breathhold noncontrast thoracic MRA using highly accelerated parallel imaging with a 32-element coil array.Revisiting the risks of MRI with Gadolinium based contrast agents-review of literature and guidelines.Viability assessment after conventional coronary angiography using a novel cardiovascular interventional therapeutic CT system: Comparison with gross morphology in a subacute infarct swine model.Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents.Changing trends in a decade of vascular radiology-the impact of technical developments of non-invasive techniques on vascular imaging.Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis?A comprehensive literatures update of clinical researches of superparamagnetic resonance iron oxide nanoparticles for magnetic resonance imaging.Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases.Consistency of T2WI-FS/ASL fusion images in delineating the volume of nasopharyngeal carcinoma.Gadolinium and nephrogenic systemic fibrosis: time to tighten practice.Comparison of the sensitivity of a pre-MRI questionnaire and point of care eGFR testing for detection of impaired renal function.Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study)Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature.Nephrogenic systemic fibrosis: a nephrologist's perspective.Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis.Investigating progressive unexplained renal impairment and hypertensionGadolinium and nephrogenic systemic fibrosis: association or causation.Introductory Chemistry: A Molar Relaxivity Experiment in the High School Classroom.Comparison between a linear versus a macrocyclic contrast agent for whole body MR angiography in a clinical routine setting.Gadolinium - is it to blame?Pathophysiology of gadolinium-associated systemic fibrosisNephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 casesNanoscale metal-organic frameworks for biomedical imaging and drug delivery.Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis.Skeletal muscle metastases on magnetic resonance imaging: analysis of 31 casesSelf-tracking of contrast kinetics for automatic triggering of contrast-enhanced whole-heart coronary magnetic resonance angiography.
P2860
Q24645215-AD803C82-AF0E-45FA-ABCF-5327EA93AB12Q24654124-88D1C2BE-21DB-4B34-9275-0B03386E49AEQ30474483-F9F68FA5-0154-414F-960E-85AEFCF15476Q30604750-6C37BCC2-0C15-4A55-840F-BB7828CD9BE4Q33684026-CEFF3A77-E9D4-4B3D-ACCB-4838E7825D5DQ33693216-5637362B-A729-4BE0-A093-33C71CC2E308Q33748364-66D5FDC2-9D19-48D9-9C9D-EF328C2AE6ABQ33899096-2A92DE06-04A1-4DF2-8AAE-E0B88596854AQ33987773-16B64A29-471D-4825-A684-78CA725BDF32Q34077618-6D9D746C-94DE-45C6-87D4-979CA6AAD631Q35123718-A00AB072-1D97-4530-8AF6-DD582C616306Q35633417-6B5C9AE4-20F4-4001-AA69-5687B4D322BCQ35664137-68A5E970-0E14-4391-8D50-4B83DA7132D9Q35719878-359FCF7C-F209-491A-883B-5A38C6444813Q35834779-C5E87566-D867-4C12-A1BE-EE0E2A293FEEQ36059081-8DC30127-47C7-4426-ABB6-39D1B1241012Q36081641-2D227007-80AE-40F7-AAC6-6600AAFC8AEDQ36129149-816E7F13-9331-4882-A888-E7A5ECD7F7D7Q36236554-3B21E412-69F0-4EA9-8495-B76C9368EAB5Q36295407-B1FF6AE8-4A3F-4407-B3F3-0C1AD057E888Q36301599-9B216B42-C3FD-4C9E-8815-5DE18D13F7B0Q36324674-0085B193-AD40-4356-AEA7-2B9714426586Q36376149-2BEA337C-0B5C-4D2C-9565-24B18EB271C5Q36538610-38ED981E-A96A-4A09-8DFD-197B5491B591Q36692517-01CD7A0B-AAD4-4407-AB14-050C88E7C81BQ36755878-86D96201-234B-41E3-A181-A7FFE1130BB9Q36915537-F31C9B29-A640-46C1-8AE7-64EB60E82A2DQ36952499-D0E9A361-2F95-492B-8256-466D98F52BC1Q36985258-87FA78EC-4640-48C1-8AE7-979E9083CE0FQ37011625-0F638C18-4149-4E02-A265-D5957CE985DFQ37067538-763E068F-C64C-4FB4-98A5-46EA6C4BF456Q37069946-8A896D47-555F-43D8-AEF5-B3514848978AQ37078458-1F823066-BAEB-4647-ACBA-A0311BE2764CQ37133328-CFA0BBD6-1744-4A10-A0F8-3C9994F773A1Q37139482-ED387873-B7DF-4437-A85E-686B5E5C10BCQ37145493-8F5BD035-E8DF-44FE-8161-7CF5783D9C77Q37182960-AC54AA63-8CE7-4EC2-BBFD-A4285674C3A4Q37219177-84BF9342-B37C-4664-AE1C-A9108F7AA1A3Q37237353-95FF83F5-F574-4DD4-924D-EA86144ADCB5Q37248815-96F01235-B88C-4077-B55E-D7CC2AB9D5DC
P2860
Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Gadodiamide-associated nephrog ...... iologists should be concerned.
@ast
Gadodiamide-associated nephrog ...... iologists should be concerned.
@en
type
label
Gadodiamide-associated nephrog ...... iologists should be concerned.
@ast
Gadodiamide-associated nephrog ...... iologists should be concerned.
@en
prefLabel
Gadodiamide-associated nephrog ...... iologists should be concerned.
@ast
Gadodiamide-associated nephrog ...... iologists should be concerned.
@en
P2093
P356
P1476
Gadodiamide-associated nephrog ...... iologists should be concerned.
@en
P2093
Alfred C Cottrell
Dale R Broome
Gerald A Kirk
Ingrid Kjellin
Mark S Girguis
Pedro W Baron
P304
P356
10.2214/AJR.06.1094
P407
P577
2007-02-01T00:00:00Z